Latest news
Nippon Shinyaku Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.stsimplywall.st · Sun, 09 Aug 2026 01:11:35 GMTNippon Shinyaku (TSE:4516) Secures Tadekinig Alfa US Rights, Is The Valuation Gap Justified? - simplywall.stsimplywall.st · Thu, 06 Aug 2026 19:06:28 GMTTABLE-Nippon Shinyaku -Q1 group results (IFRS) - TradingViewTradingView · Thu, 06 Aug 2026 03:00:00 GMTCapricor seeks court intervention in fight over DMD cell therapy launch - FirstWord PHARMAFirstWord PHARMA · Wed, 05 Aug 2026 07:00:00 GMTAB2 Bio receives USD 30 million from Nippon Shinyaku - Greater Geneva Bern area (GGBa)Greater Geneva Bern area (GGBa) · Mon, 03 Aug 2026 12:07:14 GMTAB2 Bio Receives $30 Million From Nippon Shinyaku For U.S. Tadekinig Alfa Rights, With Up To $600 Million In Milestones And Royalties - Pulse 2.0Pulse 2.0 · Mon, 03 Aug 2026 01:58:58 GMTAPAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla - SmartkarmaSmartkarma · Sun, 02 Aug 2026 01:43:09 GMTNS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S. - PR NewswirePR Newswire · Thu, 30 Jul 2026 13:03:00 GMT